Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)

[1]Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163410.1200/JCO.2007.14.7116Search in Google Scholar

[2]Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med20083591757176510.1056/NEJMoa0804385Search in Google Scholar

[3]Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013;31:759-765.PeetersMDouillardJYVanCutsem EMutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumabJ Clin Oncol20133175976510.1200/JCO.2012.45.1492Search in Google Scholar

[4]Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.VanCutsem EKohneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med20093601408141710.1056/NEJMoa0805019Search in Google Scholar

[5]Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715-721.LoupakisFRuzzoACremoliniCKRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerBr J Cancer200910171572110.1038/sj.bjc.6605177Search in Google Scholar

[6]Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010;5:e8802.LurkinIStoehrRHurstCDTwo multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genesPLoS One20105e880210.1371/journal.pone.0008802Search in Google Scholar

[7]Hacker E, Nagore E, Cerroni L, et al. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. J Invest Dermatol 2013;133:1027-1033.HackerENagoreECerroniLNRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populationsJ Invest Dermatol20131331027103310.1038/jid.2012.385Search in Google Scholar

[8]Park SJ, Sun JY, Hong K, et al. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Clin Chem Lab Med 2013;51:1673-1680.ParkSJSunJYHongKApplication of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysisClin Chem Lab Med2013511673168010.1515/cclm-2012-0375Search in Google Scholar

[9]Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011;164:776-784.LeeJHChoiJWKimYSFrequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysisBr J Dermatol201116477678410.1111/j.1365-2133.2010.10185.xSearch in Google Scholar

[10]Oliner KSD, J.Y.; Siena,S.; Tabernero,J.; Burker,M. Analysis of KRAS/NRAS and BRAF Mutations in the Phase 3 Study of Panitumumab (pmab) + FOLFOX vs FOLFOX as 1st-Line Treatment (tx) for Metastatic Colorectal Cancer (mCRC) in J Clin Oncol 2013.Oliner KSDJ.Y.SienaS.TaberneroJ.BurkerM.Analysis of KRAS/NRAS and BRAF Mutations in the Phase 3 Study of Panitumumab (pmab) + FOLFOX vs FOLFOX as 1st-Line Treatment (tx) for Metastatic Colorectal Cancer (mCRC)J Clin Oncol201310.1200/jco.2013.31.15_suppl.3511Search in Google Scholar

[11]Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25:1995-2001.MissiagliaEJacobsBD’ArioGDistal and proximal colon cancers differ in terms of molecular, pathological, and clinical featuresAnn Oncol2014251995200110.1093/annonc/mdu275Search in Google Scholar

[12]Heinemann VM, P.D.; von Weikersthal, L.F.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.; Heintges, T.; Lerchenmuller, C.A.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Giessen, C.A.; Jung, A.; Kirchner, T.; Stintzing, S. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 2014;32.Heinemann VMP.D.von WeikersthalL.F.DeckerT.KianiA.Vehling-KaiserU.Al-BatranS.HeintgesT.LerchenmullerC.A.KahlC.SeipeltG.KullmannF.StauchM.ScheithauerW.HeldS.GiessenC.A.JungA.KirchnerT.StintzingS.Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trialJ Clin Oncol20143210.1200/jco.2014.32.15_suppl.3600Search in Google Scholar